

NOV 30 2007

400 Garden City Plaza – Suite 300
Garden City, New York 11530
(516) 742-4343 - Telephone
(516) 742-4366 - Facsimile
e-mail: intprop@ssmp.com

**SCULLY, SCOTT, MURPHY
& PRESSER, P.C.**

Fax

To: Examiner Kendra D. Carter
Group Art Unit: 1617
Confirmation No.: 5994 **From:** Xiaochun Zhu, Ph.D.

Fax: 571-273-8300 **Pages:** 8 (including cover)

Phone: **Date:** November 30, 2007

Re: Michael Xilinas, et al.
U.S. Patent Application No. 10/717,182 **CC:**
Filed: November 18, 2003
Docket: 18381A

Urgent **For Review** **Please Comment** **Please Reply** **Please Recycle**

The following is attached hereto:

1. General Transmittal (in duplicate);
2. Response Under 37 C.F.R. §§1.111 & 1.143;
3. Certificate of Facsimile.

If you have any problems concerning this facsimile, please call (516) 742-4343 and for Elyssa Hudes.

CONFIDENTIALITY: The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right or publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.

NOV 30 2007

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

Applicant(s): Michael XILINAS, et al.

Docket No.
18381A

| | | | |
|---|----------------------------------|------------------------------|------------------------|
| Application No. 10/717,182 | Filing Date November 18, 2003 | Examiner Kendra D. Carter | Group Art Unit 1617 |
| Invention: USE OF PHANQUINONE FORE THE TREATMENT OF ALZHEIMER'S DISEASE | | | |

I hereby certify that this

RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143*(Identify type of correspondence)*is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. (571) 273-8300)on November 30, 2007*(Date)***Xiaochun Zhu***(Typed or Printed Name of Person Signing Certificate)**(Signature)*

Note: Each paper must have its own certificate of mailing.

NOV 30 2007

TRANSMITTAL LETTER
(General - Patent Pending)Docket No.
18381A

In Re Application Of: Michael XILINAS, et al.

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------------|------------------|--------------|----------------|------------------|
| 10/717,182 | November 18, 2003 | Kendra D. Carter | 23389 | 1617 | 5994 |

Title: USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143

In the above identified application,

- No additional fee is required.
- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Signature

Dated: November 30, 2007

Xiaochun Zhu
Reg. No. 56,311
SCULLY, SCOTT, MURPHY & PRESSER, P.C.

TG/XZ:eh

CC:

| | |
|--|--|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on | |
| (Date) | |
| Signature of Person Mailing Correspondence | |
| Typed or Printed Name of Person Mailing Correspondence | |

P16A/REV04

NOV 30 2007

TRANSMITTAL LETTER
(General - Patent Pending)Docket No.
18381A

In Re Application Of: Michael XILINAS, et al.

| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|-------------------|------------------|--------------|----------------|------------------|
| 10/717,182 | November 18, 2003 | Kendra D. Carter | 23389 | 1617 | 5994 |

Title: USE OF PHANQUINONE FOR THE TREATMENT OF ALZHEIMER'S DISEASE

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143

in the above identified application.

- No additional fee is required.
- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Signature

Dated: November 30, 2007

Xiaochun Zhu
Reg. No. 56,311
SCULLY, SCOTT, MURPHY & PRESSER, P.C.

TG/XZ:eh

CC:

| | |
|--|--|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____ | |
| (Date) _____ | |
| _____ <i>Signature of Person Mailing Correspondence</i> | |
| _____ <i>Typed or Printed Name of Person Mailing Correspondence</i> | |

P16A/REV04

RECEIVED
CENTRAL FAX CENTER

NOV 30 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michel Xilinas, et al.

Examiner: Kendra D. Carter

Serial No: 10/717,182

Art Unit: 1617

Filed: November 18, 2003

Docket: 18381A

For: USE OF PHANQUINONE FOR
THE TREATMENT OF ALZHEIMER'S
DISEASE

Dated: November 30, 2007

Confirmation No.: 5994

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143


Sir:

In response to the Office Action dated November 5, 2007, setting forth a requirement for restriction, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, Applicants provisionally elect, with traverse, the subject matter of Group I, claims 6, 13 and 42-63 drawn to a pharmaceutical composition, for continued prosecution.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to (571) 273-8300 at the Patent and Trademark Office on the date shown below.

Dated: November 30, 2007


Xiaochun Zhu